Press Release Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes 4 hours ago
Press Release Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity Aug 13
Press Release Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights Aug 5